Bioline RX Ltd Sponsored ADR (BLRX) has released an update.
BioLineRx Ltd has announced promising results from a Phase 1 clinical trial evaluating motixafortide for mobilizing stem cells in patients with sickle cell disease. The study suggests that motixafortide, alone or combined with natalizumab, can effectively mobilize the necessary stem cells for gene therapies in a single apheresis cycle. These findings could potentially enhance the treatment process and accessibility of gene therapy for individuals with sickle cell disease.
For further insights into BLRX stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Super Micro Computer (SMCI) Says Special Committee Found No Evidence of Fraud
- Netflix’s France and Netherlands Offices Raided for Possible Tax Fraud
- Class Action Lawsuit Against Bumble Inc. (NASDAQ:BMBL)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
